{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:27:09Z","timestamp":1793366829254,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T00:00:00Z","timestamp":1466208000000},"content-version":"vor","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemistry & Biology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.chembiol.2015.05.009","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T01:50:44Z","timestamp":1433555444000},"page":"755-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1091,"title":["Hijacking the E3\u00a0Ubiquitin Ligase Cereblon to Efficiently Target BRD4"],"prefix":"10.1016","volume":"22","author":[{"given":"Jing","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanak","family":"Raina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James\u00a0D.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew\u00a0P.","family":"Crew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig\u00a0M.","family":"Crews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2015.05.009_bib1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2015.05.009_bib2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1073\/pnas.1422165112","article-title":"An in-tumor\u00a0genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma","volume":"112","author":"Baratta","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2015.05.009_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.chembiol.2015.05.009_bib4","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in pre-clinical B-cell tumor models and synergizes with targeted drugs","volume":"21","author":"Boi","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.chembiol.2015.05.009_bib5","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.celrep.2014.08.025","article-title":"Inducible in\u00a0vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition","volume":"8","author":"Bolden","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2015.05.009_bib6","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/anie.201307761","article-title":"Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system","volume":"53","author":"Buckley","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.chembiol.2015.05.009_bib7","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/biot.201100054","article-title":"Current progress of siRNA\/shRNA therapeutics in clinical trials","volume":"6","author":"Burnett","year":"2011","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.chembiol.2015.05.009_bib8","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2015.05.009_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","article-title":"Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma","volume":"24","author":"Chapuy","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.chembiol.2015.05.009_bib10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2015.05.009_bib11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2014.08.069","article-title":"Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4","volume":"9","author":"Fernandez","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2015.05.009_bib12","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2015.05.009_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2015.05.009_bib14","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/sj.onc.1210852","article-title":"BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells","volume":"27","author":"French","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.chembiol.2015.05.009_bib15","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014241","article-title":"MYC activation is a hallmark of cancer initiation and maintenance","volume":"4","author":"Gabay","year":"2014","journal-title":"Cold Spring Harbor Perspect. Med."},{"key":"10.1016\/j.chembiol.2015.05.009_bib16","article-title":"Process for the preparation of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione compounds","author":"Ge","year":"2007","journal-title":"US Pat. Appl."},{"key":"10.1016\/j.chembiol.2015.05.009_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.molonc.2012.02.004","article-title":"Discovery of small molecule cancer drugs: successes, challenges and opportunities","volume":"6","author":"Hoelder","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.chembiol.2015.05.009_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beem.2003.08.002","article-title":"The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer","volume":"18","author":"Howell","year":"2004","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.chembiol.2015.05.009_bib19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2015.05.009_bib20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4155\/fmc.10.21","article-title":"Strategies for discovering and derisking covalent, irreversible enzyme inhibitors","volume":"2","author":"Johnson","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.chembiol.2015.05.009_bib21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","article-title":"Advances in the understanding of MYC-induced lymphomagenesis","volume":"149","author":"Klapproth","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.chembiol.2015.05.009_bib22","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.18632\/oncotarget.1873","article-title":"Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL","volume":"5","author":"Loosveld","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.chembiol.2015.05.009_bib23","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.chembiol.2015.05.009_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Loven","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2015.05.009_bib25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2015.05.009_bib26","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in\u00a0cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2015.05.009_bib27","doi-asserted-by":"crossref","first-page":"C244","DOI":"10.1158\/1535-7163.TARG-13-C244","article-title":"Development of the BET bromodomain inhibitor OTX015","volume":"12","author":"Noel","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.chembiol.2015.05.009_bib28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET bromodomain inhibition","volume":"3","author":"Puissant","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2015.05.009_bib29","doi-asserted-by":"crossref","first-page":"11057","DOI":"10.1074\/jbc.R109.078105","article-title":"Chemical inducers of targeted protein degradation","volume":"285","author":"Raina","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2015.05.009_bib30","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2015.05.009_bib31","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","article-title":"Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation","volume":"2","author":"Sakamoto","year":"2003","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.chembiol.2015.05.009_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/cbic.200400274","article-title":"Chemical approaches to controlling intracellular protein degradation","volume":"6","author":"Schneekloth","year":"2005","journal-title":"Chembiochem"},{"key":"10.1016\/j.chembiol.2015.05.009_bib33","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","article-title":"Chemical genetic control of protein levels: selective in\u00a0vivo targeted degradation","volume":"126","author":"Schneekloth","year":"2004","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.chembiol.2015.05.009_bib34","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.1158\/0008-5472.CAN-14-0305","article-title":"BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in\u00a0vivo","volume":"74","author":"Shao","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2015.05.009_bib35","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.chembiol.2015.05.009_bib36","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1158\/1078-0432.CCR-12-3904","article-title":"Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer","volume":"19","author":"Shimamura","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.chembiol.2015.05.009_bib37","article-title":"Preparation and formulation of thienotriazolodiazepine derivatives for the treatment of inflammatory intestinal diseases, venous insufficiency, and venous ulcer","author":"Sueoka","year":"1998","journal-title":"PCT Int. Appl."},{"key":"10.1016\/j.chembiol.2015.05.009_bib38","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.18632\/oncotarget.1572","article-title":"Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer","volume":"4","author":"Wyce","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.chembiol.2015.05.009_bib39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"}],"container-title":["Chemistry & Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074552115001933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074552115001933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T07:25:45Z","timestamp":1761031545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074552115001933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1074552115001933"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2015.05.009","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725540841.793510854","asserted-by":"object"}]},"ISSN":["1074-5521"],"issn-type":[{"value":"1074-5521","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hijacking the E3\u00a0Ubiquitin Ligase Cereblon to Efficiently Target BRD4","name":"articletitle","label":"Article Title"},{"value":"Chemistry & Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2015.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}